RINVOQ (updadacitinib) works by targeting a specific part of the immune system (Janus Kinase) to reduce the overactive response associated with psoriatic arthritis.

What is RINVOQ?

How Is It Used?

RINVOQ is a pill (15mg) that is taken once per day.

People Who Can Take RINVOQ

The U.S. Food and Drug Administration (FDA) approved RINVOQ to treat adults living with psoriatic arthritis in 2021. RINVOQ is also approved to treat conditions other than psoriatic arthritis including rheumatoid arthritis.

What Are the Risks?

RINVOQ may increase your chance of:

  • Serious infections
  • Cancer
  • Major cardiovascular events such as heart attack or stroke
  • Blood clots
  • Tears in the stomach or intestines

Common Side Effects

In clinical trials, the most common side effects were upper respiratory infections, nausea, cough, fever, and acne.

Using RINVOQ With Other Treatments

RINVOQ may not be safe to use with certain prescriptions including JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, or certain over-the-counter (OTC) medications. Talk to your health care provider about whether using any other treatments with Otezla is right for you.

Two older men smiling in a kitchen.

New Treatment for PsA

The U.S. FDA approves upadacitinib for the treatment of adults with active psoriatic arthritis.

Read more

Psoriasis 101

Newly diagnosed? Want a refresher? Dr. Jason E. Hawkes is here to break down the science of psoriatic disease.

Learn more

Getting the Care You Need and Deserve

There is help available to get the treatment your health care provider has prescribed.

Read more

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2023 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.